title: Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory.
abstract: OBJECTIVE
  To study the use of Jianjining in the treatment of myasthenia gravis (MG) patients with a deficiency of both spleen and kidney via the theory on the combination of disease with syndrome.
  
  
  METHODS
  Sixty MG patients with a deficiency of both spleen and kidney were randomly divided into an treatment group (n = 30) treated with Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide) and a control group (n = 30) treated with Jianjining granules. The dosage of the three drugs was reduced over the course of treatment. After 3 and 6 months of treatment, the curative effect was evaluated with the muscle weakness severity scale (MWSS).
  
  
  RESULTS
  The MWSS score after treatment declined significantly in both groups. The score in the treatment group was much lower tha that in the control group (P < 0.05). The total effective rate was 63.33% (19/30) in the treatment group and 36.67% (11/30) in the control group after 3 months of treatment, and 80.00% (24/30) and 50.00% (15/30), respectively, after 6 months of treatment. The obvious and total effective rates in the treatment group were much higher than those in the control group (P < 0.05). After 6 months of treatment, there were no obvious differences (P > 0.05) in the obvious and effective rates between the 2 groups. However, the total effective rate in the treatment group was much higher than that in the control group (P < 0.01).
  
  
  CONCLUSIONS
  Using the theory on the combination of disease with syndrome, we found that the curative effect of Jianjining and Western Medicine on MG patients with deficiency of both spleen and kidney is worth further exploration.
authors.affiliation: Traditional Chinese Medicine Department of Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai 200030, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Jiang
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.forename: Yan
authors.initials: Y
authors.lastname: Liang
authors.forename: Shaobo
authors.initials: S
authors.lastname: Qiu
authors.forename: Wenjing
authors.initials: W
authors.lastname: Bao
authors.forename: Jingsheng
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000503:physiopathology; D013154:Spleen / Q000187:drug effects / Q000503:physiopathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal